AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Strategic Partnership to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced a strategic partnership to advance the development of biomarkers for Alzheimer’s disease and other neurodegenerative conditions. The agreement provides Fujirebio access to clinical samples and data collected as part of the ongoing Phase 3 Alzheimer’s disease study launched by AriBio in Dec. 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230308005122/en/
AriBio completed a Phase 2 study in 2021 in mild to moderate Alzheimer’s disease patients with their lead compound AR1001, a PDE5 inhibitor with preclinical efficacy shown to inhibit neuron apoptosis, promote neurogenesis, increase neuroplasticity, and stimulate autophagy activity to remove toxic proteins. The Phase 3 study in patients with early Alzheimer’s disease, AR1001-ADP3-US01, has been launched in the United States and plans to expand to other countries in 2023.
Fujirebio, a trusted partner for high-quality IVD testing solutions and a pioneer in neurodegenerative disease diagnostics is committed to the advancement of biomarkers to improve diagnosis of Alzheimer’s disease. Fujirebio was the first company to develop and market cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease testing and the first to receive FDA authorization in 2022 for its Lumipulse® G β-Amyloid Ratio (1-42/ 1-40) test. Fujirebio continues to make advances in the field to provide fully automated blood-based tests for Alzheimer’s disease and other neurological disorders.
“AriBio is committed to advancing not just the treatment options for patients with Alzheimer’s disease and their families, but also the development of better diagnostics and improved characterization of this devastating disease. This initial partnership with Fujirebio is the first of several we plan to launch in the next few years as we expand our clinical programs into other areas of neurodegeneration. Fujirebio is an ideal partner for us and reflects our commitment to advancements in this space. We look forward to working closely with Fujirebio to improve the detection of Alzheimer’s disease and other neurodegenerative diseases with their pioneering assays,” commented James Rock, President of AriBio Co., Ltd US Office.
“Fujirebio continues to lead the industry in the development of high quality, functional tests to improve clinicians’ ability to detect and diagnose a variety of neurodegenerative conditions. We continue to partner with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools,” stated Monte Wiltse, President and CEO of Fujirebio Diagnostics, Inc.
AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
Fujirebio Diagnostics, Inc., a wholly owned subsidiary of H.U. Group Holdings, Inc. and Fujirebio Holdings, Inc., is a premier diagnostics company and the industry leader in cancer biomarker tests. Fujirebio Diagnostics specializes in the contract development and manufacturing for the diagnostics industry leaders and market development of novel in-vitro diagnostic products for the management of human disease states. For more information about Fujirebio Diagnostics, please call +1 610-240-3800 or visit us at www.fujirebio.com. H.U. Group Holdings, Inc. (formerly known as Miraca Holdings Inc.) is a listed company on the Tokyo Stock Exchange – TYO: 4544.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005122/en/
James Rock – AriBio
Chris Dague – Fujirebio
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chef Marcus Samuelsson Invests in Aleph Farms, Plans to Serve Aleph Cuts Cultivated Steaks7.6.2023 16:14:00 EEST | Press release
Aleph Farms, a cellular agriculture company designing new ways to grow quality animal products, today announced that Chef Marcus Samuelsson is joining the company as an investor, culinary advisor and launch partner. Through much of his rise to fame as the celebrity chef behind 13 restaurants around the world, a New York Times best-selling author and a TV personality, Samuelsson has been using his unique background to elevate diversity in the culinary world. As part of this designation, he will work closely with Aleph Farms as it approaches commercialization of Aleph Cuts, the world’s first cultivated steaks, providing a new take on steak. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005267/en/ Marcus Samuelsson x Didier Toubia (Credit: Noi Einav) “Aleph Farms builds partnerships based on shared values. Like us, Chef Marcus believes in making a positive impact on our food systems with creativity, courage, and care,” s
Merz Therapeutics’ XEOMIN® (incobotulinumtoxinA) receives new therapeutic indication for the United Kingdom7.6.2023 16:09:00 EEST | Press release
Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) for the use of XEOMIN® for the treatment of focal spasticity of the lower limb affecting the ankle joint. The approval, which previously included upper limb spasticity, has now been extended, enabling Merz Therapeutics to offer holistic support to people in the UK living with spasticity who require comprehensive treatment. “The label extension in the UK is an important step for Merz Therapeutics and the patients that we serve. With the UK becoming the second market, following Japan, to grant approval for the treatment of lower limb spasticity, affecting the ankle joint, it establishes the UK as the pioneering European country in this area. This approval supports our strong commitment to bringing better outcomes to more patients,” says Stefan König, CEO Merz Therapeutics. Enabling holist
Wipro and Cisco Launch Managed Private 5G-as-a-Service Solution to Accelerate Enterprise Digital Transformation7.6.2023 16:05:00 EEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today launched a managed private 5G-as-a-Service solution in partnership with Cisco (NASDAQ: CSCO). The new offering enables enterprise customers to achieve better business outcomes through the seamless integration of private 5G with their existing LAN/WAN/Cloud infrastructure. The changing nature of work and digital transformation across Information Technology (IT) and Operational Technology (OT) infrastructures are being driven by 5G and other complementary technologies. Managed private 5G from Cisco and Wipro supports organizations looking to enjoy the advantages of a private 5G network without having to acquire, run, and maintain one. The as-a-service solution benefits enterprise customers by minimizing the risks associated with upfront capital expenditure (Capex) investments and expedites technology adoption as Wipro and Cisco take on the technical, operational, and commercial
SoftServe Acquires Hoverstate7.6.2023 16:01:00 EEST | Press release
SoftServe, a global IT consulting firm, today announced its acquisition of Hoverstate, a full-service digital agency specializing in mobile and web-based solutions. The acquisition positions both companies as a single software solution source for digital native organizations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005221/en/ SoftServe, a global IT consulting firm, has announced acquiring Hoverstate, a full-service digital agency specializing in mobile and web-based solutions. (Graphic: Business Wire) SoftServe’s dynamic offerings and global footprint enhance Hoverstate’s intelligent process automation expertise and its key partnership with the Pega Platform from Pegasystems, the low-code platform provider empowering the world’s leading enterprises to Build for Change®. Clients now have deeper access to accelerated cloud-based digital processes and increased developmental efficiencies using data and analytics, A
Rimini Street’s Street Smart and Street Light Executive Series Strives to Bring Together Thousands of Global CXOs, IT and Finance Leaders into a Unique Community of Peer Learning, Networking and Sharing of Ideas7.6.2023 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, sees markedly increased participation in its Street Smart and Street Light executive series, with the most recent Street Smart event hosted in Tokyo, Japan in May 2023 bringing together nearly 200 influential CXOs and IT leaders into a single gathering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005369/en/ Rimini Street’s Street Smart and Street Light executive series gain popularity with CXOs and IT leaders. (Photo: Business Wire) Attendees of the increasingly popular Rimini Street global events recognize and appreciate the exceptional quality of dialogue, new regional and industry connections and inclusion in an exclusive community of dynamic professionals eager to help one another navigate co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom